Trial
NCT04665375
Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Health Network, Toronto
Collaborators
Merck Canada Inc.
Condition
Hiv
Intervention
DOR/3TC/TDF
Why stopped
enrollment futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-16